WaveMan
WaveMan · Company
PEPG · Pepgen Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PEPG PepGen (PEPG) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001835597
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
27
13F, latest reported quarter

What the filings say about PEPG

Insiders, 180 days
-$1.7K net sold
1 seller · 0% of sales under a 10b5-1 plan

PepGen insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, PepGen Inc. insiders sold a net $1.7K of stock across 43 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Kasraian Kasra
Chief Technical Officer
SELL
2026-05-26 SECtraded 2026-05-21
1,233
$1.7K
+63.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 2.5% of the 50,074 shares held after it.
  • No other insider sold within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technical Officer Kasraian Kasra sold about $1.7K of PEPG on May 21, 2026; 27 funds added in the latest 13F quarter.
STRECK PAUL
EVP, Head of R&D
SELL
2026-03-06 SECtraded 2026-03-04
1,832
$11.4K
-55.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 30, 2025.
  • The trade is 2.4% of the 76,273 shares held after it.
  • 2 other insiders sold within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Head of R&D STRECK PAUL sold about $11.4K of PEPG on Mar 4, 2026, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 27 funds added in the latest 13F quarter.
STRECK PAUL
EVP, Head of R&D
SELL
2026-03-06 SECtraded 2026-03-04
47
$296
-55.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 30, 2025.
  • The trade is 0.1% of the 76,226 shares held after it.
  • 2 other insiders sold within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Head of R&D STRECK PAUL sold about $296 of PEPG on Mar 4, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 27 funds added in the latest 13F quarter.
Donnelly Noel
Chief Financial Officer
SELL
2026-03-06 SECtraded 2026-03-04
2,032
$12.7K
-55.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 26, 2025.
  • The trade is 1.8% of the 111,655 shares held after it.
  • 2 other insiders sold within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Donnelly Noel sold about $12.7K of PEPG on Mar 4, 2026, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 27 funds added in the latest 13F quarter.
Donnelly Noel
Chief Financial Officer
SELL
2026-03-06 SECtraded 2026-03-04
52
$329
-55.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 26, 2025.
  • The trade is 0.0% of the 111,603 shares held after it.
  • 2 other insiders sold within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Donnelly Noel sold about $329 of PEPG on Mar 4, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 27 funds added in the latest 13F quarter.
43 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 38 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.7K over 180 days
more than 63% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
27 funds bought in last quarter
below 63% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
11.7% of the float short (float per yahoo 2026-10-26) · 4.8 days to cover · settled 2026-09-30
more than 57% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PEPG

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-44.7%12M
-70%-27%+16%+59%2025-102025-122026-022026-042026-062026-082026-10 2026-03-04 · McArthur James G sold $32.0K2026-03-04 · Donnelly Noel sold $12.7K2026-03-04 · STRECK PAUL sold $11.4K2026-05-21 · Kasraian Kasra sold $1.7K2026-03-04 · McArthur James G sold $8292026-03-04 · Donnelly Noel sold $3292026-03-04 · STRECK PAUL sold $296
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PEPG: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
20,064,545 sh
$36.1M
Commodore Capital LP
4,475,000 sh
$8.1M
VIKING GLOBAL INVESTORS LP
3,482,434 sh
$6.3M
Laurion Capital Management LP
2,750,855 sh
$5.0M
ADAR1 Capital Management, LLC
2,591,085 sh
$4.7M

Congress trades in PEPG

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PEPG planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

PEPG mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$154.8K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$253.4K position · as of 2026-06-30
0.0%
iShares Biotechnology ETF
$807.3K position · as of 2026-06-30
0.0%
Invesco Nasdaq Biotechnology ETF
$5.4K position · as of 2026-05-31
0.0%
1290 VT Micro Cap Portfolio
$17.1K position · as of 2026-06-30
0.0%
ProShares Ultra Nasdaq Biotechnology
$3.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
4
Phase 2
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $1.7K sold by insiders over 180 days, 27 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PEPG financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$69.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-75.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-59.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-69.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-40.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$93.6M-$97.7M-$84.8M-$68.3M
Net income-$89.7M-$90.0M-$78.6M-$69.1M
EPS (diluted)-2.12-2.85-3.30-4.42
Operating cash flow-$81.6M-$82.4M-$69.0M-$59.3M
Cash$60.5M$49.4M$80.8M$181.8M
SEC XBRL, fiscal years, as known on 2026-10-28

PEPG Stock Sonar score 4/7 axes

Find similar shapesCompare

PEPG ranks highest on profitability (38th percentile) and institutional and government (37th), and lowest on insider conviction (31st), among Pharma & Biotech peers.

Profitability
38
Inputs
  • Return on equity-75.5% · 41 pct, sector of 545
  • Return on assets-59.1% · 39 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-69.9% · 36 pct, sector of 576
Insider conviction
31
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2K · 62 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
37
Inputs
  • Funds adding, latest quarter27 · 37 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
34
Inputs
  • Short interest, % of float+11.7% · 34 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PEPG filings, in plain words

Are PepGen insiders buying or selling PEPG?

In the 180 days to 2026-10-28, PepGen insiders were net sellers, a net $1.7K across purchases and sales reported on Form 4, by 1 seller.

Read the full summary

In the 180 days to 2026-10-28, PepGen insiders were net sellers of PEPG, a net $1.7K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies